Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-03Clinical Trial Results: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 clinical trial results evaluating the efficacy and safety of ONS-5010 in subjects with neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2026-07-29Clinical Trial Results: Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration [NA]
Clinical trial results for retinal fundus flavoprotein fluorescence in geographic atrophy and age-related macular degeneration have been com…
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
Phase 3 trial assessing the safety of ONS-5010 in subjects with visual impairment due to retinal disorders completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial results for ONS-5010 in neovascular age-related macular degeneration completed with posted results.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD [Phase 2, Phase 3]
Pivotal Phase 2/3 study of ABBV-RGX-314 (RGX-314) gene therapy for neovascular age-related macular degeneration evaluates subretinal deliver…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV [Phase 2]
Phase 2 study evaluating the usability of the SB11 prefilled syringe (ranibizumab biosimilar) in participants with wet age-related macular d…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy [Phase 1, Phase 2]
A safety surveillance study of human embryonic stem cell–derived retinal pigment epithelium cell therapy for age-related macular degeneratio…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy [Phase 3]
An open-label extension of avacincaptad pegol in geographic atrophy has completed Phase 3, with results posted on April 14, 2026. The study …
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of EXG102-031 in Patients With wAMD (Everest) [Phase 1]
Phase 1 study of EXG102-031 in neovascular (wet) age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
A completed clinical trial compared the treatment burden of intravitreal anti-VEGF therapy across three retinal diseases: age-related macula…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of RO7669330 in geographic atrophy due…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: AMD Ryan Initiative Study (ARIS)
The AMD Ryan Initiative Study (ARIS) sponsored by the National Eye Institute focusing on age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
This clinical trial update notes that the National Eye Institute-sponsored study on the natural history of geographic atrophy in age-related…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material [Phase 4]
This clinical trial update reports on the efficacy of faricimab in patients with age-related macular degeneration featuring subretinal hyper…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 1, Phase 2]
An update on the ABBV-6628 intravitreal study in adults with geographic atrophy due to age-related macular degeneration, focusing on adverse…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications [NA]
A completed clinical trial evaluating surgery, intravitreal tissue plasminogen activator, and antiangiogenic therapy for subretinal haemorrh…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy [Phase 2]
Phase 2 clinical trial update on dimethyl fumarate to slow geographic atrophy in age-related macular degeneration; the study is currently re…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration [NA]
A completed clinical trial studied how anti-angiogenic therapy impacts the blood-aqueous barrier in exudative age-related macular degenerati…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy [Phase 1]
Phase 1 trial update on autologous intravitreal CD34+ stem cells for retinopathy; the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration [Phase 1, Phase 2]
Elisigen, Inc. reports a Phase 1/2 clinical trial evaluating NG101, an AAV gene therapy, for wet age-related macular degeneration. The study…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration [Phase 1]
This update describes a Phase 1 follow-up study to evaluate the safety of RetinoStat in Age-related macular degeneration, with the trial cur…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration [Phase 1]
Phase I, open-label, multicenter, dose-escalation study evaluating the safety and tolerability of KH658 gene therapy in participants with ne…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy [Phase 1, Phase 2]
A clinical trial update indicates Kamuvudine-8 is being evaluated for Geographic Atrophy in Phase 1/2 and the study is currently active but …
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe [Phase 3]
A Phase 3 trial evaluating pegcetacoplan (Syfovre) in a prefilled syringe for geographic atrophy secondary to age-related macular degenerati…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration [Phase 3]
Phase 3 efficacy evaluation comparing BAT5906 to Lucentis in neovascular age-related macular degeneration has completed, with efficacy data …